Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

LY4086940

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

Eli Lilly · Phase 2 · Not yet recruiting · Enrollment 460

NCT07890376

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
LY4086940 Dose 1n/rn/rn/rn/r
LY4086940 Dose 2n/rn/rn/rn/r
LY4086940 Dose 3, Titration Schedule An/rn/rn/rn/r
LY4086940 Dose 3, Titration Schedule Bn/rn/rn/rn/r
LY4086940 Dose 4n/rn/rn/rn/r
LY4086940 Dose 5n/rn/rn/rn/r
LY4086940 Dose 6, Titration Schedule An/rn/rn/rn/r
LY4086940 Dose 6, Titration Schedule Bn/rn/rn/rn/r
LY4086940 Dose 6, Titration Schedule Cn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • LY4086940 Dose 1: endpoint not reported
  • LY4086940 Dose 2: endpoint not reported
  • LY4086940 Dose 3, Titration Schedule A: endpoint not reported
  • LY4086940 Dose 3, Titration Schedule B: endpoint not reported
  • LY4086940 Dose 4: endpoint not reported
  • LY4086940 Dose 5: endpoint not reported
  • LY4086940 Dose 6, Titration Schedule A: endpoint not reported
  • LY4086940 Dose 6, Titration Schedule B: endpoint not reported
  • LY4086940 Dose 6, Titration Schedule C: endpoint not reported
  • Placebo: endpoint not reported